<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0A353A6C-0C6B-4373-887A-AB02A26B6A6F"><gtr:id>0A353A6C-0C6B-4373-887A-AB02A26B6A6F</gtr:id><gtr:name>The Lieber Institute for Brain Development</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3F9D3189-E90A-484F-BC4C-CC0381D47A4E"><gtr:id>3F9D3189-E90A-484F-BC4C-CC0381D47A4E</gtr:id><gtr:name>Center for Genomics and Transcriptomics (CEGAT)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:department>Sch of Molecular. Genetics &amp; Pop Health</gtr:department><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0A353A6C-0C6B-4373-887A-AB02A26B6A6F"><gtr:id>0A353A6C-0C6B-4373-887A-AB02A26B6A6F</gtr:id><gtr:name>The Lieber Institute for Brain Development</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3F9D3189-E90A-484F-BC4C-CC0381D47A4E"><gtr:id>3F9D3189-E90A-484F-BC4C-CC0381D47A4E</gtr:id><gtr:name>Center for Genomics and Transcriptomics (CEGAT)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/349A380A-1097-45AC-ACEE-D801E72E4F6B"><gtr:id>349A380A-1097-45AC-ACEE-D801E72E4F6B</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:otherNames>Mark</gtr:otherNames><gtr:surname>McIntosh</gtr:surname><gtr:orcidId>0000-0002-0198-4588</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A272DBEA-0D1F-4203-B758-69698FC352F1"><gtr:id>A272DBEA-0D1F-4203-B758-69698FC352F1</gtr:id><gtr:firstName>Siddharthan</gtr:firstName><gtr:surname>Chandran</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/FDFB2775-4424-4E71-8D9C-7F6EFA24FC95"><gtr:id>FDFB2775-4424-4E71-8D9C-7F6EFA24FC95</gtr:id><gtr:firstName>Kirsty</gtr:firstName><gtr:surname>Millar</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FJ004367%2F1"><gtr:id>E25FFAC8-4DF2-4FE8-B143-F96F500325DD</gtr:id><gtr:title>Modelling psychosis using DISC1 human induced pluripotent stem cells</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/J004367/1</gtr:grantReference><gtr:abstractText>Schizophrenia and major mental illness are very common conditions whose aetiology is imperfectly understood and for which our treatments are only partially effective. They are known to be highly familial (genetic) and some genetic risk factors, including those affecteing the DISC locus, are sufficient to cause these disorders in a large proportion of individuals who carry them. It is also known that abnormalities of brain structure and function are closely linked to these genetic factors. The cellular mechanisms underlying these abnormalities and clinical disorder are however still unclear, largely becuase the human brain is inaccessable in vivo. However, it has recently become possible to study brain cells in vitro by reprogramming skin fibroblasts to become neurones and other neural cell types.
 We propose to study in vitro neural tissue derived from individuals with and without disease-causing translocation at the DISC locus. First, we will reprogramme their fibroblasts to become pluripotent stem cells, neural progenitors and neurons which will then be extensively validated and characterised. We will then examine how disease risk is conferred at a cellular level through a series of comparative studies of neural progenitor proliferation, neuronal morphology and physiology, and later by focussing specifically on the processes affected DISC1/2 and glutamate (NMDA) receptor expression.</gtr:abstractText><gtr:technicalSummary>Schizophrenia and major mental illness are devastating conditions with a combined lifetime prevalence of over 10%. Whilst partially effective treatments are available, none are clearly disease modifying. Notwithstanding important insights provided by animal models there is a great and unmet need for further models of mental illness in order to develop more effective therapies. The t(1;11) translocation1, discovered in a large multiply affected Scottish family in very close contact with the Division of Psychiatry, is one of the strongest single genetic risk factors identified for major psychiatric disorders. Combining genetic discoveries with advances in reprogramming and resulting derivation of human induced pluripotent stem cell lines (hIPS) now allows human based disease models and several studies have demonstrated the feasibility of this approach for both neurological and psychiatric disorders. 
 The current proposal brings together major strengths in clinical psychiatry - specifically our ongoing and long-term study of the t(1;11) family, neurophysiology, molecular genetics, stem cell biology and in vitro disease modelling. We propose to develop a human in vitro model of psychosis by obtaining and then validating induced pluripotent stem cells, neural progenitors and forebrain neurons from individuals with and without the t(1;11) translocation. We will then conduct a number of comparative studies examining the effects of the translocation on neuronal structure and function, dendritic arborisation and spine density, before examining the effects on DISC1/DISC2 and NMDAR expression.</gtr:technicalSummary><gtr:potentialImpactText>In addition to the academic beneficiaries of the proposed work, there are wider impacts that will involve patients, health care providers and the pharmaceutical industry.

1. Patients and health care providers
The fundamental objective of this clinically-driven research proposal is to further our understanding of disease biology in psychosis and to develop a platform to develop and test new and more effective drug treatments. The abnormalities discovered in cells from individuals in the current study are likely to lead to an improved understanding of disease biology, since they address the relevent tissue types in vivo and in human subjects for the first time. These insights will lead to more rational therapies targetted to the underlying abnoramlities in these individuals and therefore may lead to persoanlised treatments targetted to an individuals specific undrelying pathophysiology.

2. Pharmaceutical industry
By elucidating the cellular disease phenotype in the current proposal, this will immediately create a system whereby we can attempt to reverse these changes using existing therapies and new chemical entities. These cells may therefore enable a novel platform for drug developmentusing the most relevent tissue type, in vitro. Potentially this may increase the proportion of effective drugs that entre phase III trials and reduce the need for animal based studies.</gtr:potentialImpactText><gtr:fund><gtr:end>2015-05-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>414509</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Lieber Institute for Brain Development</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Collaboration with Lieber Institute and Astra Zeneca</gtr:description><gtr:id>1435B485-0C0A-4C14-A30B-47420B24903E</gtr:id><gtr:impact>This is multi-disciplinary collaboration between genetics, genomics and cell biology labs at Lieber, Edinburgh - including collaborators in drug development at Astra Zeneca.</gtr:impact><gtr:outcomeId>58483eb9125ef0.48978999-1</gtr:outcomeId><gtr:partnerContribution>Sample sent to LIBD under MTA and are being processed through their pipelines for the derivation of neuronal tissue and their functional genomic and e-physiology pipelines. They are being compared to large numbers of samples from individuals with schizophrenia where there is no-known causal variant, those with penetrant causal variants and individuals highly burdened with common variants of low-penetrance.</gtr:partnerContribution><gtr:piContribution>We have provided carefully quality controlled fibroblast and induced pluripotent stems cells from a well-known family who carry a causal mutation for schizophrenia.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Center for Genomics and Transcriptomics (CEGAT)</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Comparative RNAseq analysis of mouse model and human DISC1 t(1;11) translocation cell lines</gtr:description><gtr:id>4D43FBD6-14A1-4E92-94B9-144EF289D451</gtr:id><gtr:impact>We have characterise a rare human variant that is causal for schizophrenia and related psychiatric disorders</gtr:impact><gtr:outcomeId>56e31045e655d4.76106014-1</gtr:outcomeId><gtr:partnerContribution>CEGAT have provided RNA sequencing analysis of the RNA obtained from human t(1;11) neuronal cell lines and from a mouse model of the translocation</gtr:partnerContribution><gtr:piContribution>We have contributed RNA and cell lines to the centre for Genomics and Transcriptomics</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Human Genetics Unit</gtr:department><gtr:description>Bioinformatic collaboration with MRC HGU</gtr:description><gtr:id>E0545897-25B6-4265-B4B5-538497A46AA5</gtr:id><gtr:impact>We have been able to characterise novel transcripts from DISC1-derived cell lines that may explain the cell's abnormal function and the subsequent development of schizophrenia</gtr:impact><gtr:outcomeId>56e30f4313b3d9.74101561-1</gtr:outcomeId><gtr:partnerContribution>Our partners have provided bioinformatic analysis of the data from RNAseq analysis.</gtr:partnerContribution><gtr:piContribution>We have provided RNA and RNA sequence data from DISC1 iPS-derived neuronal cell lines</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1959067</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>NIH R01</gtr:description><gtr:end>2015-07-02</gtr:end><gtr:fundingOrg>National Institutes of Health (NIH)</gtr:fundingOrg><gtr:id>1B5B27F9-9362-4644-B5B4-1F3B79F34E32</gtr:id><gtr:outcomeId>544a34876e7280.70548188</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>400000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Eva Lester Bequest to the University of Edinburgh</gtr:description><gtr:end>2019-11-02</gtr:end><gtr:fundingOrg>University of Edinburgh</gtr:fundingOrg><gtr:id>469EEC85-22F8-4AE0-A34D-96F6E0C3127C</gtr:id><gtr:outcomeId>58483fee267d70.08810459</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>4750000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Wellcome Trust Institutional Strategic Support Fund</gtr:department><gtr:description>Wellcome Trust Strategic Award</gtr:description><gtr:end>2019-12-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>104036/Z/14/Z</gtr:fundingRef><gtr:id>D5B3C480-9AEA-4642-956B-9811EDAC4EDE</gtr:id><gtr:outcomeId>544a2b16acd127.64678762</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>420000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>EU Framework 7</gtr:description><gtr:end>2017-12-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:fundingRef>IMAGEMEND</gtr:fundingRef><gtr:id>F9D327F8-1E57-4018-831F-E6F18D46D9CA</gtr:id><gtr:outcomeId>544a35a51b1337.71099349</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Sackler Endowment</gtr:description><gtr:end>2017-07-02</gtr:end><gtr:fundingOrg>Dr Mortimer and Theresa Sackler Foundation</gtr:fundingOrg><gtr:id>FE55FFD3-50A0-4C11-994D-6A71264CEC09</gtr:id><gtr:outcomeId>otB2fyZ32H6</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>The Sackler Institute of the Universities of Edinburgh and Glasgow</gtr:description><gtr:end>2020-12-02</gtr:end><gtr:fundingOrg>Dr Mortimer and Theresa Sackler Foundation</gtr:fundingOrg><gtr:id>B22094BD-9145-42F7-8E43-C15A58AD4220</gtr:id><gtr:outcomeId>5848404da3cfb0.60797796</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>998000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRACK-IT</gtr:description><gtr:end>2015-08-02</gtr:end><gtr:fundingOrg>National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs)</gtr:fundingOrg><gtr:fundingRef>BADIPS</gtr:fundingRef><gtr:id>E85BBAAC-10BE-4F9E-B925-6D655701A4D5</gtr:id><gtr:outcomeId>mKggjrNbxgi</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2012-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have successfully reprogrammed fibroblasts from the DISC1 family and made confirmed induced pluripotent stem cell lines</gtr:description><gtr:id>6C2D4165-DCED-4ED4-8536-5075F6468603</gtr:id><gtr:impact>This has so far demonstrated proof of concept.</gtr:impact><gtr:outcomeId>kGu9yMLP9Yq</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>DISC1 Induced Pluripotent Stem Cells</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have banked fibroblasts and induced pluripotent stem cells from individuals carrying a balanced translocation at the DISC locus (Chromosome 1) and Chromosome 11.</gtr:description><gtr:id>DDFC256E-26AE-4CD7-964C-9D40D8EB0768</gtr:id><gtr:impact>The cells will be valuable to the research community (and the pharmaceutical industry) in future. They are required for successful completion of the study but will have important uses outside of the planned investigations</gtr:impact><gtr:outcomeId>d51xEM5Q54a</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>DISC1 translocation cell lines</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have derived neuronal cells from two clones of induced pluripotent stem cell lines: one from a patient carrying a translocation between chromosomes 1 and 11, the other from a karyotypicaly normal subject</gtr:description><gtr:id>9DFAFB5B-56F8-4F2D-B490-41E24B511A1C</gtr:id><gtr:impact>This material will enable one the hypotheses regarding DISC1 fusion transcripts to be addressed</gtr:impact><gtr:outcomeId>MT1Joknpamf</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>DISC1 early iPSC neurons</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>5B5B7906-D4AF-408D-BC2D-F6D506437156</gtr:id><gtr:title>Functional properties of in vitro excitatory cortical neurons derived from human pluripotent stem cells.</gtr:title><gtr:parentPublicationTitle>The Journal of physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a870ddbc6f40ddea0dc8f5449c90bb5d"><gtr:id>a870ddbc6f40ddea0dc8f5449c90bb5d</gtr:id><gtr:otherNames>Livesey MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-3751</gtr:issn><gtr:outcomeId>585d3a46da91d8.22888175</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A45D1A92-4927-4FCC-9E40-D20861611DA2</gtr:id><gtr:title>Ionotropic GABA and glycine receptor subunit composition in human pluripotent stem cell-derived excitatory cortical neurones.</gtr:title><gtr:parentPublicationTitle>The Journal of physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/df9f5c795da682635ad8c66ad17bd403"><gtr:id>df9f5c795da682635ad8c66ad17bd403</gtr:id><gtr:otherNames>James OT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-3751</gtr:issn><gtr:outcomeId>544a332696c398.38592037</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EAB31A9E-F8B7-469F-BC83-3F3BFA900373</gtr:id><gtr:title>Effects of a Balanced Translocation between Chromosomes 1 and 11 Disrupting the DISC1 Locus on White Matter Integrity.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/546aab6570de14e108d67dbe21ff57d0"><gtr:id>546aab6570de14e108d67dbe21ff57d0</gtr:id><gtr:otherNames>Whalley HC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>56a22c52096d57.89930749</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6936295F-DDB8-4622-A0D9-BDC6772AF54B</gtr:id><gtr:title>Maturation and electrophysiological properties of human pluripotent stem cell-derived oligodendrocytes.</gtr:title><gtr:parentPublicationTitle>Stem cells (Dayton, Ohio)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a870ddbc6f40ddea0dc8f5449c90bb5d"><gtr:id>a870ddbc6f40ddea0dc8f5449c90bb5d</gtr:id><gtr:otherNames>Livesey MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1066-5099</gtr:issn><gtr:outcomeId>585d6df0eaa057.18350921</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CABC6E86-2BF7-499E-AA9D-EBBAA1FB0363</gtr:id><gtr:title>DISC1 as a genetic risk factor for schizophrenia and related major mental illness: response to Sullivan.</gtr:title><gtr:parentPublicationTitle>Molecular psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a539e3129d8da0b342323406bfd41a0"><gtr:id>4a539e3129d8da0b342323406bfd41a0</gtr:id><gtr:otherNames>Porteous DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1359-4184</gtr:issn><gtr:outcomeId>54b5020669a008.92336444</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4FACD10D-85E2-4843-8AF5-D1296ECAE9A6</gtr:id><gtr:title>Improved PCR based methods for detecting C9orf72 hexanucleotide repeat expansions.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular probes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9ad8463930a592be12cc992cdc683c92"><gtr:id>9ad8463930a592be12cc992cdc683c92</gtr:id><gtr:otherNames>Cleary EM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0890-8508</gtr:issn><gtr:outcomeId>585d457891e572.05297061</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>65785165-AEED-4082-A218-76A06B7CDB38</gtr:id><gtr:title>The cortical thickness phenotype of individuals with DISC1 translocation resembles schizophrenia.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c66500625ad889fb130796efe084218f"><gtr:id>c66500625ad889fb130796efe084218f</gtr:id><gtr:otherNames>Doyle OM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>56a22c4e485401.87635563</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>408FEBA7-80E4-41A8-86C5-73CBC8AB08A1</gtr:id><gtr:title>708 Common and 2010 rare DISC1 locus variants identified in 1542 subjects: analysis for association with psychiatric disorder and cognitive traits.</gtr:title><gtr:parentPublicationTitle>Molecular psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e3b94f079dbd8fda5a117d2570e555e4"><gtr:id>e3b94f079dbd8fda5a117d2570e555e4</gtr:id><gtr:otherNames>Thomson PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1359-4184</gtr:issn><gtr:outcomeId>54b50205c4c8a1.60876034</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/J004367/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>3C193D18-12BD-4B15-8347-037BA623E0FF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Mental Health</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>